Concerns about the Ethanol Blended Petrol (EBP) programme refuse to die down in Andhra Pradesh, with scientists and farmers saying water resources are depleting and emissions from factories are ...

In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. and put ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats. Trump ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

The Environmental Protection Agency (EPA) will proceed with Biden-era plans to allow the year-round sale of higher-ethanol E15 fuel, a longtime ask of midwestern lawmakers and the biofuels industry.

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic improvement at Week 12 of its phase 2 ulcerative colitis trial. The new duvakitug data also clear up the ...

COLUMBUS, Ohio -- Ohio Attorney General Dave Yost has joined the fight for year-round access to an ethanol fuel blend that could lower gas prices. “Ohio’s motorists, farmers and energy ...

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...